Stay updated with breaking news from Program Background Information. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
02.05.2024 - KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of ...
02.11.2023 - First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from partner Sanofi; dosing of first patient in Phase 2 AD trial expected in the fourth quarter of 2023 ASH abstract to be ...
Information and Communications Technology Consultancy in Georgia, requiring 5-9 years of experience, from EPF; closing on 20 Jun 2021